Tender detail
Successive supply of medicines
Summary
The tender concerns the successive supply of medicines with two active substances: amivantamab 3520 mg vial and amivantamab 2400 mg vial. The company should note that the exact qualification, exclusion and compliance requirements were not stated in the machine-readable notice and must be checked in the tender documents.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.